tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TBPH Stock Latest News

Promising Outlook for Theravance Biopharma: Buy Rating Backed by Phase 3 CYPRESS Trial Developments
RatingsPromising Outlook for Theravance Biopharma: Buy Rating Backed by Phase 3 CYPRESS Trial Developments
3d ago
TBPH
Theravance Completes Enrollment in Phase 3 CYPRESS Study
PremiumCompany Announcements
Theravance Completes Enrollment in Phase 3 CYPRESS Study
4d ago
8K
TBPH
Theravance Biopharma completes enrollment in CYPRESS study
PremiumThe Fly
Theravance Biopharma completes enrollment in CYPRESS study
4d ago
TBPH
Theravance Biopharma Settles Patent Dispute with Cipla
PremiumCompany Announcements
Theravance Biopharma Settles Patent Dispute with Cipla
9d ago
8K
TBPH
Theravance Biopharma: Strong Product Performance and Promising Growth Prospects Justify Buy Rating
PremiumRatings
Theravance Biopharma: Strong Product Performance and Promising Growth Prospects Justify Buy Rating
14d ago
TBPH
Theravance Biopharma’s Earnings Call Highlights Strategic Gains
PremiumCompany AnnouncementsTheravance Biopharma’s Earnings Call Highlights Strategic Gains
15d ago
TBPH
Theravance Biopharma’s Strong Growth Potential Backed by Yupelri Success and Pipeline Advancements
Premium
Ratings
Theravance Biopharma’s Strong Growth Potential Backed by Yupelri Success and Pipeline Advancements
16d ago
TBPH
Theravance Biopharma Reports Strong Q2 2025 Results
Premium
Company Announcements
Theravance Biopharma Reports Strong Q2 2025 Results
16d ago
TBPH
Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty
PremiumRatings
Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty
16d ago
TBPH
Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)
PremiumThe Fly
Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)
17d ago
TBPH
Theravance Biopharma reaffirms FY25 R&D expenses view $32M-$38M
PremiumThe Fly
Theravance Biopharma reaffirms FY25 R&D expenses view $32M-$38M
17d ago
TBPH
TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
19d ago
TBPH
Theravance Biopharma price target raised to $25 from $24 at BTIG
PremiumThe FlyTheravance Biopharma price target raised to $25 from $24 at BTIG
2M ago
TBPH
Theravance Biopharma Gains Milestone Payment from Viatris
Premium
Company Announcements
Theravance Biopharma Gains Milestone Payment from Viatris
2M ago
8K
TBPH
Theravance Biopharma announces Viatris approval for Yupelri in China
Premium
The Fly
Theravance Biopharma announces Viatris approval for Yupelri in China
2M ago
TBPH
VTRS
Theravance Biopharma initiated with a Buy at JonesResearch
PremiumThe Fly
Theravance Biopharma initiated with a Buy at JonesResearch
2M ago
TBPH
Promising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA Treatment
PremiumRatings
Promising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA Treatment
2M ago
TBPH
Theravance Biopharma Settles Patent Litigation with Eugia
PremiumCompany Announcements
Theravance Biopharma Settles Patent Litigation with Eugia
3M ago
8K
TBPH
Theravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth Uncertainty
PremiumRatings
Theravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth Uncertainty
3M ago
TBPH
Theravance Biopharma’s Strategic Moves and Growth Potential Justify Buy Rating
PremiumRatingsTheravance Biopharma’s Strategic Moves and Growth Potential Justify Buy Rating
3M ago
TBPH
Theravance Biopharma Sells Trelegy Royalty Interest to GSK
Premium
Company Announcements
Theravance Biopharma Sells Trelegy Royalty Interest to GSK
3M ago
8K
TBPH
Theravance to sell remaining royalty interest in Trelegy to GSK for $225M
Premium
The Fly
Theravance to sell remaining royalty interest in Trelegy to GSK for $225M
3M ago
GSK
TBPH

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >